Scholarlink

<p>Colorectal cancer (CRC) is a common malignant tumor of the digestive system. The standard chemotherapy (CT) regimen for metastatic CRC (mCRC) is FOLFIRI, etc., but CT plus bevacizumab anti-epidermal growth factor receptor (EGFR)monoclonal antibody (mAb) (cetuximab) can improve the therapeutic effect. This article compared the effect of FOLFIRI plus bevacizumab on the clinical treatment of mCRC. One hundred eight patients with mCRC were divided into cohort A (CA, bevacizumab FOLFIRI CT, <i>n</i> = 50) and cohort B (CB, cetuximab + FOLFIRI CT, <i>n</i> = 58). All patients received 6 cycles of CT. The levels of tumor markers, angiogenic factors, and T lymphocyte subsets were compared, and the objective response rate (ORR) and disease control rate (DCR) were counted. The overall survival (OS), progression-free survival (PFS), and adverse reactions (AR) were recorded. There was no difference in DCR (82.0% vs 89.7%), serum tumor markers, angiogenic factors, T lymphocyte subsets (CD3 + , CD4 + , and CD8 +), and DFS (16.0% vs 24.1%) in subjects; as against CA, the ORR (62.0% vs 75.9%), CD4 + /CD8 + ratio, and OS (32.0% vs 46.6%) were significantly increased, and the VEGF level was significantly higher in CB (<i>P</i> &lt; 0.05). Compared with bevacizumab plus FOLFIRI, cetuximab plus FOLFIRI has significantly higher ORR and longer OS in the treatment of patients with mCRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Zhehui Lin

摘要

Colorectal cancer (CRC) is a common malignant tumor of the digestive system. The standard chemotherapy (CT) regimen for metastatic CRC (mCRC) is FOLFIRI, etc., but CT plus bevacizumab anti-epidermal growth factor receptor (EGFR)monoclonal antibody (mAb) (cetuximab) can improve the therapeutic effect. This article compared the effect of FOLFIRI plus bevacizumab on the clinical treatment of mCRC. One hundred eight patients with mCRC were divided into cohort A (CA, bevacizumab FOLFIRI CT, n = 50) and cohort B (CB, cetuximab + FOLFIRI CT, n = 58). All patients received 6 cycles of CT. The levels of tumor markers, angiogenic factors, and T lymphocyte subsets were compared, and the objective response rate (ORR) and disease control rate (DCR) were counted. The overall survival (OS), progression-free survival (PFS), and adverse reactions (AR) were recorded. There was no difference in DCR (82.0% vs 89.7%), serum tumor markers, angiogenic factors, T lymphocyte subsets (CD3 + , CD4 + , and CD8 +), and DFS (16.0% vs 24.1%) in subjects; as against CA, the ORR (62.0% vs 75.9%), CD4 + /CD8 + ratio, and OS (32.0% vs 46.6%) were significantly increased, and the VEGF level was significantly higher in CB (P < 0.05). Compared with bevacizumab plus FOLFIRI, cetuximab plus FOLFIRI has significantly higher ORR and longer OS in the treatment of patients with mCRC.